Morphic Holding Inc (MORF): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Morphic Therapeutic (MORF)

The price-to-sales chart, which reflects the impact of Morphic Holding, Inc. (MORF) being acquired by a major holding company and the integration of its pipeline, has now reached a value of 2674.60, marking the metric's latest reading. This growth is driven by the patent protection of the MInT platform and FDA oversight. However, fierce competition in the VZK niche against industry behemoths creates risks of losing insurance reimbursements.

morphictx.com (MORF) - P/S Multiple from 07/04/2022 to 04/26/2024

Analytical breakdowns for Morphic Holding Inc (MORF)

- current quotes and average value forecast:
Market Price morphictx.com|MORF - Price Target Chart
- stock exchange capitalization data:
Market Value Morphic Holding Inc|MORF - Total Company Value
- book capitalization indicators:
Share Book Value Morphic|MORF - Book Capitalization|Market Value to Book Value morphictx.com|MORF - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Morphic Holding, Inc.|MORF - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Morphic Holding Corp|MORF - Company Total Debt|Debt to Net Assets Ratio Morphic Holding Inc|MORF - Company Long-Term Debts|Company Short-Term Loans and Borrowings Morphic|Immediate Liquidity morphictx.com
- earnings and valuation multiples indicators:
MORF - Company Net Income|Expected Profit Morphic Holding, Inc.|MORF - P/E Multiple|Price to Future Earnings Ratio Morphic Therapeutic|MORF - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Morphic Holding Inc|MORF - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Morphic|MORF - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year morphictx.com|MORF - Net earnings per share growth this year|Expected earnings per share trend next year Morphic Holding, Inc.
- issuer revenue and sales details:
MORF - Revenue and Sales Volume|Company Future Sales morphictx.com|MORF - Price-to-Revenue Ratio|Market Cap to Projected Revenue Morphic Holding Inc
Summary company analytics:morphictx.com, MORF
Core merchandise of Morphic Holding, Inc.

The integration of the Morphic Holding, Inc. (MORF) R&D platform into the Lilly structure shifts the company's business model into a stage of proprietary development synergy. This price-to-sales multiple determines the ratio of the business's market value to its annual sales, allowing investors to assess the fairness of asset valuations relative to actual cash flow by analyzing the risk of being overbought or undervalued through the price action on this chart.

Competing companies

PHAT - Price to Sales|Price-to-Revenue Ratio Terns Pharmaceuticals, Inc. TERN|Market Capitalization-to-Revenue Ratio IRWD|CURX - Price-to-Revenue Ratio|Price-to-Sales Ratio IMRN|EVOK: P/S Multiple|Entero Therapeutics - Market Capitalization-to-Revenue Ratio|RDHL (RedHill Biopharma Ltd) - P/S Multiple|Palisade Bio Inc. (PALI) - Price-to-Revenue Coefficient|P/S Multiple JAGX|Market Cap to Revenue Biora Therapeutics, Inc BIOR